Eplerenone and Clinical Outcomes in Heart Failure: A Comparative Analysis

Background: Mineralocorticoid receptor antagonism is an established component of evidence-based heart-failure management, but its effects on cardiac function, congestion biomarkers, functional capacity, hospitalization, mortality, and laboratory safety must be interpreted within the context of the underlying study design. This manuscript demonstrates how a structured synthetic dataset can be analysed across these domains without implying that the results are observed clinical evidence. Methods: The workbook contained 160 synthetic participants, evenly divided between an Eplerenone group (n=80) and a Control group (n=80). Variables included pre/post ejection fraction (EF), BNP, six-minute walk distance, blood pressure, heart rate, creatinine, potassium, NYHA class, all-cause and cardiac hospitalizations, cardiac death, all-cause death, event timing, and follow-up duration. Descriptive comparisons were calculated from the supplied workbook after a quality audit. Results: In the synthetic illustration, mean EF change was 3.91 percentage points with Eplerenone versus 1.08 with Control. Mean BNP reduction was 25.16% versus 3.42%, and mean six-minute walk improvement was 48.96 versus 5.97 m. All-cause hospitalization occurred in 12/80 (15.00%) versus 21/80 (26.25%); cardiac hospitalization in 8/80 (10.00%) versus 18/80 (22.50%). Cardiac death was recorded in 0 Eplerenone participants and 2 Controls; all-cause death was recorded in 1 (1.25%) and 5 (6.25%), respectively. These figures are descriptive properties of the simulation and do not estimate a real treatment effect. Conclusion: The workbook supports a complete, reproducible analysis framework for EF, BNP, exercise capacity, hospitalization, mortality, and safety monitoring. It does not support causal inference or claims of eplerenone efficacy. A publishable clinical manuscript would require source-verified observations, a prespecified protocol, ethics oversight, and an appropriate inferential analysis.

Authors

Publication Details

Journal
NIU Journal of Health Sciences
Published
2026-11-16
DOI
https://doi.org/10.58709/niujhs.v12i3.2777
Primary Topic
Heart Failure Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Eplerenone and Clinical Outcomes in Heart Failure: A Comparative Analysis

Sabah Hadi Sachet
NIU Journal of Health Sciences
Heart Failure Treatment and Management
article

Eplerenone and Clinical Outcomes in Heart Failure: A Comparative Analysis

Sabah Hadi Sachet
article en

Abstract

Background: Mineralocorticoid receptor antagonism is an established component of evidence-based heart-failure management, but its effects on cardiac function, congestion biomarkers, functional capacity, hospitalization, mortality, and laboratory safety must be interpreted within the context of the underlying study design. This manuscript demonstrates how a structured synthetic dataset can be analysed across these domains without implying that the results are observed clinical evidence. Methods: The workbook contained 160 synthetic participants, evenly divided between an Eplerenone group (n=80) and a Control group (n=80). Variables included pre/post ejection fraction (EF), BNP, six-minute walk distance, blood pressure, heart rate, creatinine, potassium, NYHA class, all-cause and cardiac hospitalizations, cardiac death, all-cause death, event timing, and follow-up duration. Descriptive comparisons were calculated from the supplied workbook after a quality audit. Results: In the synthetic illustration, mean EF change was 3.91 percentage points with Eplerenone versus 1.08 with Control. Mean BNP reduction was 25.16% versus 3.42%, and mean six-minute walk improvement was 48.96 versus 5.97 m. All-cause hospitalization occurred in 12/80 (15.00%) versus 21/80 (26.25%); cardiac hospitalization in 8/80 (10.00%) versus 18/80 (22.50%). Cardiac death was recorded in 0 Eplerenone participants and 2 Controls; all-cause death was recorded in 1 (1.25%) and 5 (6.25%), respectively. These figures are descriptive properties of the simulation and do not estimate a real treatment effect. Conclusion: The workbook supports a complete, reproducible analysis framework for EF, BNP, exercise capacity, hospitalization, mortality, and safety monitoring. It does not support causal inference or claims of eplerenone efficacy. A publishable clinical manuscript would require source-verified observations, a prespecified protocol, ethics oversight, and an appropriate inferential analysis.

NIU Journal of Health SciencesVol. 12(3)
Good health and well-being
Heart Failure Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon